Recent development of engineered T cell therapies has demonstrated remarkable efficacy and brought hope to cancer patients. However, many challenges still remain in their cell productions since patients’ T cells as starting materials are exhausted and weak, have a vast variation in quality, and are very hard to expand. For those reasons, iPSC-derived engineered immune cells gain increasing attentions from many biotech companies and pharmaceutical companies. Thyas is a start-up company, pioneering producing iPS cell-derived T cells (iPS-T), NK cells, and other immune cells for the treatment of cancers. Thyas’ technology, developed by Dr. Shin Kaneko, a professor at the Center of iPS cell Research and Application (CiRA), Kyoto University, Japan, makes it possible to manufacture the large number of iPSC-derived immune cells with potent cytotoxicity, significant proliferative capacity, and excellent persistency in vivo. The therapeutic benefits are expected to be treating patients with no/few or exhausted immune cells, breaking through an immunosuppressive microenvironment with large numbers of iPSC-derived immune cells, and completely removing cancer cells without significant side effects. Thyas’ first product is an off-the-shelf type of iPS-T cells targeting solid tumors with a tumor antigen specific T cell receptor (TCR-iPS-T), which is currently in a preclinical stage. In addition, Thyas is in collaboration with Kyoto University to support an ongoing clinical trial with iPSC-derived NK cells (iPS-NK) in Japan. Importantly, those iPSC-derived immune cells could be a platform to take any CARs or TCRs. Demonstration of safety and preliminary efficacy of those products in clinical trials would promote the use of iPS cell-derived immune cells for many other cancers through alliances with biotech companies and pharmaceutical companies.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 46-29 Yoshida-Shimo-Adachi-Cho, Sakyo-Ku,, Kyoto,kyoto 6068501,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- thyas.co.jp
- Keywords
- Life science, immunotherapy, cell therapy, iPS Cell, Cancer, startup, venture, Kyoto, Kyoto University, research & development, Clinical trial, Finance, ライフサイエンス, がん免疫, 細胞医療, iPS細胞, ベンチャー, スタートアップ, 京都, 京都大学, 治験, 臨床試験, ベンチャーキャピタル.
- HQ
- Kyoto, Kyoto
Thyas Co. Ltd. Questions
Thyas Co. Ltd.'s website is thyas.co.jp
Thyas Co. Ltd.'s LinkedIn profile is https://jp.linkedin.com/company/thyas
Thyas Co. Ltd. has
5 employees.
View email and phone details for 5
employees at Thyas Co. Ltd..
Thyas Co. Ltd.'s industry is
Biotechnology Research
Thyas Co. Ltd.'s top competitors are
Bioactive Services ( Bioactive Resources And Safe Sterilization Usa ),
Nephrogen,
Foundation Medicine,
Shape Therapeutics Inc.,
Kenai Therapeutics,
Bicara Therapeutics,
Innate Pharma,
Tune Therapeutics,
Shinobi Therapeutics,
Vor Bio.
Thyas Co. Ltd.'s categories are Biotechnology Research
Thyas Co. Ltd.'s founding year is 2015
